- and LPS-Induced
Nitrite Production by Rat Alveolar Macrophages
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
Abstract |
|---|
|
|
|---|
Although several studies have demonstrated that the pulmonary collectins surfactant protein (SP)-A and SP-D contribute
to innate immunity by enhancing pathogen phagocytosis, the
role of SP-A and SP-D in regulating production of free radicals
and cytokines is controversial. We hypothesized that the state
and mechanism of activation of the immune cell influence its
response to SP-A. The effects of SP-A and SP-D on production
of nitric oxide (NO) and inducible nitric oxide synthase (iNOS)
were assessed in isolated rat alveolar macrophages activated
with lipopolysaccharide (LPS), interferon gamma (IFN-
), or
both agonists. SP-A inhibited production of NO and iNOS in
macrophages stimulated with smooth LPS, which did not significantly bind SP-A, or rough LPS, which avidly bound SP-A.
In contrast, SP-A enhanced production of NO and iNOS in cells stimulated with IFN-
or INF-
plus LPS. Neither SP-A nor SP-D affected baseline NO production, and SP-D did not significantly affect production of NO in cells stimulated with either LPS or IFN-
. These results suggest that SP-A contributes
to the lung inflammatory response by exerting differential effects on the responses of immune cells, depending on their
state and mechanism of activation.
| |
Introduction |
|---|
|
|
|---|
Pulmonary surfactant protein (SP)-A and SP-D belong to
a group of collagenous carbohydrate binding proteins
known as collectins that mediate a variety of immune cell
functions. For example, a number of studies have shown
that SP-A and SP-D stimulate immune cell chemotaxis
and the phagocytosis and clearance of a variety of pathogens (1, 2). The role of SP-A and SP-D in regulating production of cytokines and reactive species is less clear. For example, SP-A has been shown to directly stimulate (3) or
to have no effect (4) on tumor necrosis factor (TNF)-
production by immune cells. In contrast, SP-A has been
shown to inhibit lipopolysaccharide (LPS)-induced TNF-
production by alveolar macrophages (4, 6), the macrophage-like U937 cells (6), or human buffy coat cells (5).
Recently, SP-A has been reported to inhibit production of several cytokines by human alveolar macrophages and
monocytes stimulated with Candida albicans (7). To the
best of our knowledge, the effects of SP-D on cytokine
production have not been reported.
The effects of SP-A on the production of reactive nitrogen species are also controversial. For example, SP-A has
been shown to have no effect on (8) or to stimulate
(12) the production of nitric oxide (NO) by alveolar macrophages. Miles and coworkers (9) and Blau and colleagues
(12) reported that SP-A has no effect on LPS-induced NO
production by rat alveolar macrophages. Hickman-Davis
and associates (11) showed that SP-A enhanced in vitro
killing of Mycoplasma pneumoniae by alveolar macrophages from C57 BL/6 mice through a NO-dependent
mechanism. More recently, Hickman-Davis and coworkers (13) reported that SP-A-deficient mice have an increased susceptibility to M. pneumoniae infection compared with wild-type mice. In contrast, Pasula and
colleagues (10) reported that SP-A suppresses NO production by interferon (IFN)-
-treated mice alveolar macrophages in response to Mycobacterium tuberculosis. Both
SP-A (14) and SP-D (15) have been reported to stimulate
directly the production of oxygen radicals. Although endotoxin contamination can affect SP-A-mediated function
(8), the presence of endotoxin in SP-A cannot entirely explain these disparate results because SP-A containing low
levels or no detectable endotoxin has been used in many
of these investigations.
We hypothesized that the effects of SP-A and SP-D on
immune cell function may depend on the mechanism and
state of activation of immune cells. To test this hypothesis,
we examined the effects of SP-A and SP-D on the production of NO by alveolar macrophages stimulated with either LPS, IFN-
, or both agonists. The results indicate that
SP-A can exert opposite effects on immune cells activated
with different agonists.
| |
Materials and Methods |
|---|
|
|
|---|
Reagents
Water from a Picosystem water purification system (Hydro Water Systems, Research Triangle Park, NC) was used for all studies. The water quality specifications for this system include a
pyrogen content less than 0.25 endotoxin U/ml. LPS from the
LCD 25 strain of Escherichia coli K12 (Rb-LPS mutant) and LPS
of E. coli 0111:B4 (S-LPS) were purchased from List Biological
Laboratories (Campbell, CA). Low endotoxin (less than 0.1 ng/mg)
bovine serum albumin (BSA) was from Sigma Chemical (St.
Louis, MO), nitrate-free basal medium Eagle and Dulbecco's
phosphate-buffered saline were from GIBCO BRL (Grand Island, NY), and heat-inactivated fetal calf serum (FCS) was from
Atlanta Biologicals (Norcross, GA). Human C1q was from Advanced Research Technologies (San Diego, CA). Rat recombinant IFN-
at 2.2 × 105 U/ml was purchased from Calbiochem
(La Jolla, CA); the level of endotoxin in a representative preparation was 0.79 pg/U IFN-
as measured by the ACL-1000 Limulus Amebocyte Lysate kit (BioWhittaker, Walkersville, MD).
Mouse monoclonal anti-macrophage inducible nitric oxide synthase (iNOS) immunoglobulin (Ig) G and a macrophage lysate
prepared from RAW 264.7 cells stimulated with IFN-
and LPS,
which served as the standard, were from Transduction Laboratories (Lexington, KY). Horseradish peroxidase (HRP)-conjugated
rabbit anti-mouse IgG was from Pierce Laboratories (Rockford,
IL). The BIOXYTECH Nitric Oxide Assay was obtained from
OXIS International (Portland, OR). All other chemicals (except
as noted) were from Sigma Chemical (St. Louis, MO).
Purification of SP-A
SP-A was isolated from the lung lavage of patients with alveolar proteinosis as previously described in detail (16). Briefly, the whole surfactant pellet from lung lavage was extracted with butanol, butanol-insoluble proteins were resolubilized with octylglucopyranoside (OGP), and SP-A was finally solubilized in 5 mM Tris-buffered water, pH 7.4. Residual OGP was removed by dialysis against 5 mM Tris-buffered water, pH 7.4. To remove endotoxin, SP-A was treated with OGP and polymyxin B agarose beads as previously described in detail (8). SP-A preparations were tested for bacterial endotoxin using a Limulus Amebocyte Lysate assay (BioWhittaker). All SP-A preparations used contained < 0.02 pg endotoxin/µg SP-A. For some experiments, SP-A was heat-inactivated by incubation at 95°C for 10 min.
Purification of SP-D
SP-D was isolated from the lung lavage of silica-treated rats as described (17). Briefly, to induce surfactant accumulation, anesthetized rats received 25 mg silica in 0.5 ml of saline intratracheally, they were killed by exsanguination approximately 4 wk later, and their lungs were lavaged six times with 150 mM NaCl, 5 mM Tris, pH 7.4. Lavage samples were centrifuged at approximately 25,000 × g for 45 min at 4°C (model L8-70; Beckman, Fullerton, CA). The supernatant was mixed with maltose-sepharose (18) in the presence of 5 mM CaCl2 and incubated for 18 h at 4°C. The slurry was centrifuged at 2,400 × g for 10 min at 10°C. The supernatant was removed and the slurry was washed four times by resuspending the slurry in 20 mM Tris, 150 mM NaCl, 5 mM CaCl2, pH 7.8, incubating it for 10 min at room temperature, and centrifuging the mixture at 2,400 × g for 10 min. After the final wash, the supernatant was removed and the maltose-Sepharose was resuspended in 50 mM Tris, 150 mM NaCl, 10 mM ethylenediaminetetraacetic acid (EDTA), pH 7.8. The Ca2+-dependent maltose-binding proteins were eluted from the beads by washing them six times. The fractions containing the highest SP-D concentrations were pooled and further purified by gel filtration (19). To remove contaminating endotoxin, SP-D was treated with octylglucoside and polymyxin as previously described (8). The two SP-D preparations used contained 0.114 pg endotoxin/µg SP-D and 0.23 pg endotoxin/µg SP-D.
Isolation of Cells for Nitrite Measurement
Alveolar macrophages were isolated by lung lavage of specific
pathogen-free, male, Sprague-Dawley rats weighing 250 to 300 g
(Charles River Laboratory, Raleigh, NC). In brief, rats were anesthetized with pentobarbital and killed by exsanguination. The
lungs were removed and lavaged six times with a macrophage isolation buffer containing 140 mM NaCl, 6 mM glucose, 2.5 mM phosphate buffer, 10 mM N-2-hydroxyethylpiperazine-N'-ethane
sulfonic acid (Hepes), and 0.2 mM ethyleneglycol-bis-(
-aminoethyl ether)-N,N'-tetraacetic acid (EGTA), followed by two lavages with the same buffer containing 1.3 mM magnesium and
2 mM calcium and no EGTA. Lavage samples were centrifuged at
200 × g for 10 min. The cells were resuspended in nitrate-free
basal medium Eagle containing 110 mg/liter of L-glutamine, 50 U/
ml of penicillin, 50 µg/ml of streptomycin, 15 mM Hepes with 10%
(vol/vol) heat-inactivated FCS. Cell recovery routinely averaged
3 to 8 × 106 cells/animal. The viability of the cells was determined
by erythrosin B exclusion and averaged 95 to 97%. The cell lysate
fractions were assayed for protein content by the BCA method
(BCA kit; Pierce) with BSA as a standard.
Incubation Conditions
Cells were plated at 2.5 × 105 cells/well in 96-well plates (Costar,
Cambridge, MA) and allowed to attach for 2 h. The medium was
then removed and, for some conditions, alveolar macrophages were stimulated with rat recombinant IFN-
(10 or 100 U/ml) for 24 h at 37°C in a 5% CO2 atmosphere in the absence or in the
presence of SP-A or SP-D. After preincubation, Rb- or S-LPS
was added at 100 ng/ml for an additional 24 h. After 48 h, media
were removed and briefly centrifuged to remove nonadherent
cells before analysis of nitrite content. For time course experiments, cells were preincubated with SP-A (100 µg/ml) in the
presence (10 U/ml) or absence of IFN-
for 24 h; Rb-LPS (100 ng/ml) was then added for 10 min, 4, 8, 12, 16, or 24 h. In separate
experiments, cells were preincubated with SP-A (100 µg/ml) for
24 h and IFN-
(10 U/ml) was added for an additional 24 h. For
time course experiments with IFN-
and SP-A, cells were stimulated with IFN-
(10 U/ml) in the absence or presence of SP-A
(100 µg/ml) and accumulated nitrite was determined at 10 min, 6, 12, and 24 h. Cell viability was assessed by erythrosin B dye exclusion and averaged 94 to 98%.
Measurement of Nitrite Production
NO production was assessed by measuring nitrite in media fractions by the Greiss reaction as previously described (20). Nitrite
concentrations were determined from a standard curve using sodium nitrite at concentrations ranging from 6.7 to 133.3 µM. Results are expressed as nitrite concentration or as a percentage of
the levels of nitrite in the control group. For measurement of total nitrite (NO3
/NO2
), the BIOXYTECH Nitric Oxide Assay
(OXIS) was used. The kit employs affinity purified Zea Mays nitrate reductase and NADH to reduce nitrate (NO3) to nitrite
NO3. NO3 was then measured using the Greiss reaction as described previously. The standard curve ranged from 0.5 to 25 µM.
Microtiter Plate LPS Binding Assay
Immulon-2 96-well microtiter plates were coated with LCD 25 E. coli K 12 LPS or 0111:B4 E. coli LPS (5 µg/well), AP-SP-A (positive control for SP-D binding) and myosin (positive control for SP-A binding [550 ng/well]) or nothing (BSA) in 0.1 M Na2CO3, 20 mM EDTA, pH 9.6, for 3 h at 37°C. After incubation, the LPS solution was removed, and the plates were air-dried overnight. Nonspecific binding sites were blocked with 200 µl/well of 10 mg/ ml low endotoxin BSA in 50 mM Hepes, 0.15 M NaCl, pH 7.4 for 30 min. Plates were washed three times and biotinylated SP-A (bSP-A) or bSP-D (1 to 20 µg/ml) was added. Plates were incubated at 4°C overnight. After washing, biotinylated streptavidin-HRP was added at a 1:500 dilution and incubated for 3.5 h at room temperature. After additional washing, color was developed using H2O2 and 0-phenylenediamine dihydrochloride in 0.1 M citric acid, pH 5. Color reaction was stopped with 4 N H2SO4, and the color intensity was measured in a microtiter plate spectrophotometer at 490 nm.
Detection of iNOS Protein
To determine if SP-A affected LPS or IFN-
-induced iNOS levels
in alveolar macrophages, Western blot analysis was performed. Cell lysate fractions were assayed for protein content by the BCA
method (BCA kit; Pierce). Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions
was performed on either 30 or 40 µg of cell protein using either
12.5 or 15% polyacrylamide gels. The proteins were transferred to
nitrocellulose membranes, which were then blocked with 5% nonfat dry milk in 10 mM Tris, 100 mM NaCl, 0.1% Tween 20 for 1 h
at room temperature. The blots were then incubated for an additional hour at room temperature in 0.1% Tween 20 with 5% nonfat dry milk with a mouse monoclonal anti-macrophage iNOS IgG
at a dilution of 1:2,500 or 1:1,000. Membranes were then washed
three times in Tris buffer, followed by a 1-h incubation at room
temperature in blocking buffer containing HRP-conjugated rabbit
antimouse IgG at a dilution of 1:5,000 or 1:2,000. After incubation,
blots were washed three times and immunoreactive proteins were
visualized by enhanced chemiluminescence using the enhanced
chemiluminescence Western blotting detection system (Amersham Life Science, Arlington Heights, IL). A macrophage lysate
prepared from RAW 264.7 cells stimulated with IFN-
and LPS
served as the standard. Samples were also assessed for actin content. Membranes were incubated with a mouse monoclonal antiactin IgG from ascites (Chemicon Labs, Temecula, CA) at a 1:400
dilution. Rabbit antimouse IgG-HRP at a 1:5,000 dilution served
as the secondary antibody. Autoradiographs were analyzed by
densitometric scanning and analyzed using NIH image.
Statistics
Data were either analyzed with the Mann-Whitney U test or Student's t test for unpaired samples or with paired Student's t test
when expressed as percentage of the control response. Values were considered significant when P
0.05.
| |
Results |
|---|
|
|
|---|
SP-A Inhibits LPS-Induced NO Production
Consistent with previous reports from Miles and colleagues (9) and Pasula and coworkers (10), we found that SP-A alone did not induce production of detectable nitrite by alveolar macrophages incubated for up to 48 h with SP-A (Figure 1). In contrast, SP-A dramatically inhibited production of nitrite by alveolar macrophages stimulated with Rb-LPS. Preincubation of cells with SP-A for 24 h before the addition of Rb-LPS resulted in an 89, 61, and 44% inhibition of Rb-LPS-induced NO production at 12, 16, and 24 h after addition of Rb-LPS, respectively, suggesting that the inhibitory effect of SP-A is decreasing over time (Figure 1). Of note, SP-A at concentrations as high as 100 µg/ ml did not interfere with the nitrite assay (data not shown).
|
SP-A Augments IFN-
-Induced NO Production
In contrast to its inhibitory effects on LPS-induced production of NO, SP-A enhanced the production of NO by
cells stimulated with IFN-
. As shown in Figure 2, detectable enhancement was evident at 12 h and persisted over
the 24-h time course of the experiment. At 24 h, SP-A enhanced IFN-
-induced NO by approximately 200% over
the levels obtained with IFN-
in the absence of SP-A.
When SP-A was preincubated for 24 h before addition of
IFN-
, the nitrite level was 6.9 µM. IFN-
alone induced
nitrite levels of 3.2 µM. Thus, SP-A enhances nitrite induced by IFN-
when preincubated before addition of the
IFN-
or when added simultaneously with the IFN-
.
|
The effect of SP-A was dependent on the dose of IFN-
and was more pronounced at lower doses than at higher
doses (Figure 3). The enhancing effects of SP-A on IFN-
-induced NO, as well as the inhibitory effects of SP-A on
LPS-induced NO production, were dependent on the dose
of SP-A (Figure 4). SP-A also enhanced production of NO
when alveolar macrophages were stimulated with both
LPS and IFN-
(Figure 4).
|
|
The effects of SP-A on LPS and IFN-
-induced NO3
/
NO2
were analyzed by converting nitrate to nitrite and
measuring nitrite with the Greiss reaction. The trends for
the effects of SP-A on NO3
/NO2
were similar to the effects on nitrite. For example, SP-A inhibited LPS-induced
NO2
levels by 40% and inhibited NO3
/NO2
levels by
26%. In addition, SP-A enhanced NO2
levels in the presence of IFN-
by 325% and NO3
/NO2
by 141% (means
from two different experiments).
Inhibitory Effect of SP-A on LPS-Induced NO Production Does Not Require a High Degree of Binding of SP-A to LPS
To determine if SP-A inhibited LPS action by binding LPS, the effects of SP-A on macrophage responses to a smooth serotype of LPS were investigated. SP-A inhibited production of NO stimulated by S-LPS (Figure 5) as well as Rb-LPS (Figures 1 and 4) in a dose-dependent manner. As shown in Figure 6, biotinylated SP-A bound the Rb-LPS mutant in a dose-dependent manner (Figure 6A) but only minimally bound the smooth LPS serotype from E. coli 0111:B4. Biotinylated SP-D bound in a dose-dependent manner to Rb-LPS and but only slightly to S-LPS (Figure 6B); SP-D did not affect production of NO by alveolar macrophages stimulated with Rb-LPS (see subsequent text).
|
|
SP-A Affects Levels of iNOS Protein in Alveolar Macrophages
The effects of SP-A on iNOS levels were analyzed by Western blotting of macrophages stimulated with IFN-
, LPS,
or the combination of IFN-
and LPS. As shown in Figure
7A, SP-A alone had no detectable effect on iNOS levels.
Smooth LPS dramatically increased iNOS protein, and SP-A
inhibited this induction by approximately 88% at a concentration of 20 µg/ml and 99% at 100 µg/ml as assessed by densitometric analysis. SP-A also inhibited Rb-LPS-
induced iNOS protein expression (Figure 7A) by approximately 82% at a concentration of 100 µg SP-A /ml. SP-A
significantly enhanced the magnitude of IFN-
-induced
iNOS protein expression (Figure 7B). At a concentration
of 100 µg/ml, SP-A enhanced iNOS protein levels by approximately 290% after 24 h incubation.
|
Effects of SP-D and Other Immunomodulatory Proteins
on NO Formation Induced by LPS or IFN-
The two pulmonary collectins share some but not all functions (1, 2). Therefore, we assessed the role of SP-D in regulating production of NO by macrophages stimulated with
IFN-
, Rb-LPS, or Rb-LPS in combination with IFN-
. In
contrast to the inhibitory effects of SP-A, SP-D (0.1 to 100 µg/ml) had no significant effect on Rb-LPS-induced NO
production by alveolar macrophages (Table 1). Also in
contrast to SP-A, SP-D did not significantly augment NO
production in the presence of IFN-
or IFN-
plus Rb-LPS. Furthermore, neither IgG, C1q, nor heat-inactivated
SP-A affected nitrite production (Table 2) induced by Rb-LPS or IFN-
.
|
|
| |
Discussion |
|---|
|
|
|---|
The goal of this investigation was to test the hypothesis that
SP-A exerts differential effects on alveolar macrophages
that are stimulated with different agonists. This hypothesis was generated, at least in part, by contradictory reports
on the effects of SP-A on the production of cytokines and
reactive nitrogen species by immune cells from a variety
of species both in the absence and presence of pathogens
(3). Additional support for the hypothesis also comes
from our unpublished studies in which we found variable effects of SP-A on LPS-induced NO production. In some
experiments SP-A dramatically inhibited NO production
and in others it had no effect. When attempting to assess
the variables that might account for these differences, we
postulated that a contributing factor might be the immune
status of the animal, including whether or not the animals
were pathogen-free. In the current study, we investigated
the effects of SP-A on NO and iNOS protein expression induced by LPS, IFN-
, or the combination of both. Our
findings show that SP-A does indeed have opposite effects
on the production of NO induced by different agonists and
suggest that SP-A may exert both cell- and agonist-specific
effects that contribute to the inflammatory state of the lung.
Neither SP-A nor SP-D Directly Stimulates NO Production or iNOS Protein Expression by Rat Alveolar Macrophages
In the current investigation, neither SP-A nor SP-D that had been treated to reduce contaminating endotoxin (8) directly stimulated NO production by rat alveolar macrophages. These findings are consistent with those reported for SP-A by Miles and coworkers (9), also using rat alveolar macrophages, and by Pasula and associates (10), using mouse alveolar macrophages. However, these results differ from those of Blau and coworkers (12) who reported that SP-A directly stimulates nitrite production by rat alveolar macrophages. We do not know the reason for these discrepant findings. Blau and coworkers (12) reported that the SP-A used in their studies had low levels of measurable endotoxin, so it seems unlikely that the effects can be attributed to endotoxin. However, they did not use pathogen-free rats for all of their studies, whereas we did use pathogen-free animals. We speculate that, in some cases, rats that are not pathogen-free may be exposed to a stimuli that may alter both their in vivo and ex vivo cell responses.
SP-A, in Contrast to SP-D, Inhibits LPS-Induced NO Production and iNOS Protein Expression
Preincubation of cells with SP-A, but not SP-D, resulted in a significant and dose-dependent inhibition of LPS- induced NO production and iNOS protein expression. This effect of SP-A was independent of the two LPS phenotypes tested. These results are in contrast to those obtained by Miles and coworkers (9) and Blau and colleagues (12), who both reported no inhibitory effect of SP-A on LPS-induced NO production by rat alveolar macrophages. The contradictory results may depend largely on the different incubation conditions and the molar ratios of LPS and SP-A used. For example, Miles and associates (9) coincubated SP-A with LPS at a molar ratio of approximately 1:40 for 22 h; Blau and coworkers (12) coincubated SP-A with LPS at a molar ratio of approximately 1:156 for 48 h. In contrast, we used 100 ng/ml of LPS and SP-A ranging from 20 to 100 µg/ml. Thus, in our studies, the highest ratio of SP-A to LPS tested was 1:0.8. Although the precise concentration of SP-A present in vivo is not known, we have estimated that the hypophase concentration of SP-A ranges from 300 µg/ml to 1.8 mg/ml, although a large proportion of the SP-A is likely bound to lipid and not homogeneously distributed (1). Because the concentration of LPS is an important determinant of CD14-dependent and -independent cell binding and activating pathways in the presence of serum (21), some of the conflicting data may be due to differential inhibitory effects of SP-A on LPS interaction with different receptors. When we coincubated LPS and SP-A with macrophages for 24 h and then measured nitrite levels, we were unable to demonstrate consistent inhibitory effects of SP-A on LPS-induced NO production, even at high SP-A to LPS molar ratios (data not shown). These data are consistent with the possibility that an adequate time period of preincubation of cells with SP-A is necessary for optimal inhibition of LPS-induced NO. We were initially surprised that the effects of SP-A were so long lived in light of the published reports that SP-A is degraded by alveolar macrophages (22, 23). Western blot analysis of media after the 48-h incubation period showed that levels of SP-A were reduced during the incubation, but substantial amounts of SP-A remained. Thus, it appears that although SP-A is degraded, sufficient amounts remain to affect nitrite production under these experimental conditions.
Possible Mechanisms for the Differential Effects of SP-A and SP-D on LPS-Induced iNOS-Derived NO
There are several possible mechanisms by which SP-A
may inhibit LPS-induced NO production by alveolar macrophages. To determine if binding of SP-A to LPS was required for inhibition, we tested the effects of SP-A on NO
induction by two serotypes of LPS. SP-A significantly
bound Rb-LPS but only slightly bound to S-LPS. Despite this differential binding, SP-A inhibited nitrite production
induced by both serotypes of LPS. These data are consistent with reports of others showing that SP-A inhibits
LPS-mediated function independent of the degree of binding of LPS and SP-A. For example, McIntosh and coworkers (4) and Sano and colleagues (6) found that SP-A suppresses S-LPS-induced TNF-
in alveolar macrophages. In addition, Rosseau and associates (7) reported that SP-A
inhibits the production of a variety of proinflammatory cytokines by alveolar macrophages and monocytes stimulated with C. albicans and that this inhibition appears to be
independent of SP-A binding to Candida. Like SP-A (6,
24), SP-D (26) binds to Rb-LPS. Kuan and associates
(26) reported a significant binding of SP-D to Rd and Rc
E. coli LPS, but not to the Re and Ra mutants. The functional consequences of this interaction have not yet been
investigated. We now show that SP-D also significantly
and in a dose-dependent manner binds to the Rb mutant
of E. coli LPS but does not affect NO production or iNOS
protein levels induced by the same Rb-LPS mutant, suggesting that binding of LPS by SP-D is not sufficient to inhibit LPS-induced NO production.
Sano and coworkers (6) proposed that the effects of
SP-A on LPS-induced production of TNF-
occur via a direct interaction of SP-A with CD14, which is a component
of the LPS-LPS binding protein receptor (27). In their
study, SP-A inhibited TNF-
production by a smooth serotype of LPS (026:B6), which did not significantly bind to
SP-A. In contrast, SP-A did not inhibit and, in fact, increased production of TNF-
in response to a rough serotype of LPS from Re595-Salmonella minnesota, which avidly bound to SP-A. SP-A was shown to bind to CD14 and,
furthermore, SP-A enhanced binding of rough LPS and inhibited binding of smooth LPS to a soluble recombinant
CD14. We have found that SP-A enhances the binding of
3H-labeled Rb-LPS by rat alveolar macrophages in the
absence (28) and presence of serum (unpublished data).
Unlike the finding of Sano and colleagues (6) that SP-A
enhances TNF-
production induced by a rough LPS (Re-LPS from S. minnesota), we found that SP-A inhibited
TNF-
production induced by a different rough LPS (Rb-LPS from E. coli, unpublished data). It is possible that the effects of SP-A may vary with the rough LPS mutants used
or other experimental variables such as the presence and/or
type of serum used.
SP-A may also affect postreceptor events in the LPS-
induced signaling pathways for NO induction. LPS stimulation of NO and iNOS has been shown to be inhibited by
a variety of mechanisms, including elevation of intracellular cyclic adenosine monophosphate (29), inhibition of
protein kinase C activity (29), inhibition of tyrosine kinase
activity (30), and antagonists of Ca2+ channel activity (31).
Little is known about the regulation of signaling pathways
by SP-A, but the available data do not provide a clear explanation. The iNOS promoter has two nuclear factor-
B (NF-
B) binding sites as well as an IFN-stimulated response element. Koptides and coworkers (32) reported
that SP-A enhances NF-
B activity in a monocytic cell line,
THP-1. If SP-A were acting via NF-
B in our system, we
would have predicted that SP-A would inhibit NF-
B activation. However, we cannot exclude the possibility that
SP-A may elicit different responses in different cells.
SP-A Dose-Dependently Enhanced IFN-
-Induced NO
Production and iNOS Protein Levels
SP-A enhanced IFN-
-induced, iNOS-derived NO both
after preincubation of cells with SP-A for 24 h before addition of IFN-
and when both were added simultaneously.
This effect of SP-A was more pronounced at low doses of
IFN-
(10 U/ml) than at higher doses of IFN-
. In addition, not only is the inhibitory effect of SP-A on LPS-induced
NO completely abolished in the presence of low doses of
IFN-
, but the well-known synergism between IFN-
and
LPS is further increased.
The effects of SP-A on NO production induced by IFN-
in combination with another agonist or a pathogen may be
influenced by both the source of the cells and the agonist or
pathogen. For example, Pasula and coworkers (10) reported that SP-A inhibits IFN-
-induced NO production by
mouse alveolar macrophages in the presence of M. tuberculosis. In contrast, Hickman-Davis and colleagues (11) reported that SP-A enhances production of NO by mouse
macrophages stimulated with IFN-
and subsequently infected with Mycoplasma pulmonis. These results suggest
that the effects of SP-A may be pathogen specific. Hickman-Davis and colleagues (11) did not report the effects of
SP-A on IFN-
on NO production in the absence of M. pulmonis. However, Pasula and associates (10) showed that the
very low level of NO induced by IFN-
(in the absence of
M. tuberculosis) was inhibited by SP-A. These studies all
suggest that the method of activation of the cell, the pathogen to which the cells are exposed, as well as the source of
the cells may have an impact on the response of SP-A.
Possible Mechanisms for SP-A-Enhanced
IFN-
-Induced NO
We have shown that SP-A potentiates IFN-
-induced
iNOS protein expression and has a robust enhancing effect
on NO production for up to 48 h. It is unclear at this time
how SP-A exerts this enhancing effect on IFN-
-induced
NO. SP-A may enhance functionally active binding of
IFN-
to its receptor (IFN-
R) by altering the expression
of IFN-
R
-chains, which, in contrast to IFN-
R
-chains, can be upregulated by external stimuli (33). Alternatively, SP-A has been shown to trigger a rapid tyrosine, but not
serine or threonine, phosphorylation (34) of alveolar macrophage proteins and could possibly enhance/accelerate
initial phosphorylation steps of the JAK/STAT pathway,
which participates in the regulation of iNOS expression.
Finally, SP-A may enhance IFN-
-induced NO via an autocrine mechanism, for example, by increasing INF-
-induced TNF-
. However, we were unable to document SP-A-
enhanced TNF-
production in response to IFN-
after
24 h of incubation (unpublished data).
Summary
In a previous study, we investigated the role of SP-A in the
regulation of TNF-
and nitrite production induced by
LPS in wild-type and SP-A-deficient mice (35). We found
that intratracheal instillation of a smooth serotype of LPS
(026:B6) induced greater lung lavage levels of nitrite and
TNF-
in SP-A-deficient mice than in wild-type mice,
findings consistent with the in vitro studies reported here.
Important future studies include investigations of SP-A
regulation of immune cell function in SP-A-deficient mice that have been treated with IFN-
as well as studies to elucidate the mechanisms by which SP-A elicits differential
responses from cells activated with different agonists and
different pathogens.
| |
Footnotes |
|---|
Address correspondence to: Jo Rae Wright, Ph.D., Associate Professor of Cell Biology, Box 3709, Dept. of Cell Biology, Duke University Medical Center, Durham, NC 27710. E-mail: J.Wright{at}cellbio.duke.edu
(Received in original form March 8, 2000 and in revised form August 30, 2000).
Acknowledgments: The authors thank Wendy Watford, John Alcorn, Trista Schagat, and Karen Brinker for helpful discussion and comments and Patty Keating for expert technical assistance. This work was supported by grant HL-51134 from the National Heart, Lung and Blood Institute.
Abbreviations
BSA, bovine serum albumin;
HRP, horseradish peroxide;
IFN, interferon;
IFN-
R, IFN-
receptor;
Ig, immunoglobulin;
iNOS, inducible
nitric oxide synthase;
LPS, lipopolysaccharide;
NF-
B, nuclear factor
B;
NO, nitric oxide;
OGP, octylglucopyranoside;
Rb-LPS, Rb mutant of Escherichia coli LPS;
S-LPS, LPS of E. coli 0111:B4;
SE, standard error;
SP, surfactant protein;
TNF, tumor necrosis factor.
| |
References |
|---|
|
|
|---|
1. Wright, J. R.. 1997. Immunomodulatory functions of surfactant [Review]. Physiol. Rev. 77: 931-962 [Medline].
2. Crouch, E. C.. 1998. Collectins and pulmonary host defense. Am. J. Respir. Cell Mol. Biol. 19: 177-201 [Abstract/Full Text].
3. Kremlev, S. G., and D. S. Phelps. 1994. Surfactant protein A stimulation of inflammatory cytokine and immunoglobulin production. Am. J. Physiol. 267(6, Pt. 1):L712-L719.
4.
McIntosh, J. C.,
S. Mervin-Blake,
E. Conner, and
J. R. Wright.
1996.
Surfactant protein A protects growing cells and reduces TNF-alpha activity from
LPS-stimulated macrophages.
Am. J. Physiol.
15:
L310-L319
5.
Hickling, T. P.,
R. B. Sim, and
R. Malhotra.
1998.
Induction of TNF-alpha
release from human buffy coat cells by Pseudomonas aeruginosa is reduced by lung surfactant protein A.
FEBS Lett.
437:
65-69
[Medline].
6.
Sano, H.,
H. Sohma,
T. Muta,
S. Nomura,
D. R. Voelker, and
Y. Kuroki.
1999.
Pulmonary surfactant protein A modulates the cellular response to
smooth and rough lipopolysaccharides by interaction with CD14.
J. Immunol.
163:
387-395
[Abstract/Full Text].
7.
Rosseau, S.,
P. Hammerl,
U. Maus,
A. Gunther,
W. Seeger,
F. Grimminger, and
J. Lohmeyer.
1999.
Surfactant protein A down-regulates proinflammatory cytokine production evoked by Candida albicans in human alveolar macrophages and monocytes.
J. Immunol.
163:
4495-4502
[Abstract/Full Text].
8.
Wright, J. R., D. F. Zlogar, J. C. Taylor, T. M. Zlogar, and C. I. Restrepo.
1999. Effects of endotoxin on surfactant protein A and D stimulation of
NO production by alveolar macrophages. Am. J. Physiol. 276(4, Pt. 1):
L650-L658.
9.
Miles, P. R.,
L. Bowman,
K. M. K. Rao,
J. E. Baatz, and
L. Huffman.
1999.
Pulmonary surfactant inhibits LPS-induced nitric oxide production by alveolar macrophages.
Am. J. Physiol. (Lung Cell. Mol. Physiol.)
20:
L186-L196
10.
Pasula, R.,
J. R. Wright,
D. L. Kachel, and
W. J. Martin II..
1999.
Surfactant
protein A suppresses reactive nitrogen intermediates by alveolar macrophages in response to Mycobacterium tuberculosis.
J. Clin. Invest.
103:
483-490
[Abstract/Full Text].
11.
Hickman-Davis, J. M., J. R. Lindsey, S. Zhu, and S. Matalon. 1998. Surfactant protein A mediates mycoplasmacidal activity of alveolar macrophages. Am. J. Physiol. 274(2, Pt. 1):L270-L277.
12.
Blau, H., S. Riklis, J. F. Van Iwaarden, F. X. McCormack, and M. Kalina.
1997. Nitric oxide production by rat alveolar macrophages can be modulated
in vitro by surfactant protein A. Am. J. Physiol. 272(6, Pt. 1):L1198-L1204.
13.
Hickman-Davis, J.,
J. Gibbs-Erwin,
J. R. Lindsey, and
S. Matalon.
1999.
Surfactant protein A mediates mycoplasmacidal activity of alveolar macrophages by production of peroxynitrite.
Proc. Natl. Acad. Sci. USA
96:
4953-4958
[Abstract/Full Text].
14.
van Iwaarden, F.,
B. Welmers,
J. Verhoef,
H. P. Haagsman, and
L. M. van
Golde.
1990.
Pulmonary surfactant protein A enhances the host-defense
mechanism of rat alveolar macrophages.
Am. J. Respir. Cell Mol. Biol.
2:
91-98
[Medline].
15.
van Iwaarden, J. F.,
H. Shimizu,
P. H. M. van Golde,
D. R. Voelker, and
L. M. G. van Golde.
1992.
Rat surfactant protein D enhances the production of oxygen radicals by rat alveolar macrophages.
Biochem. J.
286:
5-8
[Medline].
16.
Wright, J. R.,
R. E. Wager,
S. Hawgood,
L. Dobbs, and
J. A. Clements.
1987.
Surfactant apoprotein Mr=26,000-36,000 enhances uptake of liposomes by type II cells.
J. Biol. Chem.
262:
2888-2894
[Abstract].
17.
Dethloff, L. A.,
B. C. Gladen,
L. B. Gilmore, and
G. E. Hook.
1989.
Kinetics of pulmonary surfactant phophatidylcholine metabolism in the lungs of
silica-treated rats.
Toxicol. Appl. Pharmacol.
98:
1-11
[Medline].
18.
Fornstedt, N., and
J. Porath.
1975.
Characterization studies on a new lectin
found in seeds of Vicia ervilia.
FEBS Lett.
57:
187-191
[Medline].
19.
Persson, A.,
D. Chang,
K. Rust,
M. Moxley,
W. Longmore, and
E. Crouch.
1989.
Purification and biochemical characterization of CP4 (SP-D), a collagenous surfactant-associated protein.
Biochemistry
28:
6361-6367
[Medline].
20.
Jorens, P. G.,
F. J. V. Overveld,
J. Bult,
P. A. Vermeire, and
A. G. Herman.
1991.
L-Arginine-dependent production of nitrogen oxides by rat pulmonary macrophages.
Eur. J. Pharmacol.
200:
205-209
[Medline].
21.
Gegner, J. A.,
R. J. Ulevitch, and
P. S. Tobias.
1995.
Lipopolysaccharide
(LPS) signal transduction and clearance: dual roles for LPS binding protein and membrane CD14.
J. Biol. Chem.
270:
5320-5325
[Abstract/Full Text].
22.
Wright, J. R., and
D. C. Youmans.
1995.
Degradation of surfactant lipids
and surfactant protein A by alveolar macrophages in vitro.
Am. J. Physiol.
268:
L772-L780
[Medline].
23.
Bates, S. R., and
A. B. Fisher.
1996.
Surfactant protein A is degraded by alveolar macrophages.
Am. J. Physiol.
15:
L258-L266
24.
Kalina, M., H. Blau, S. Riklis, and V. Kravtsov. 1995. Interaction of surfactant protein A with bacterial lipopolysaccharide may affect some biological functions. Am. J. Physiol. 268(1, Pt. 1):L144-L151.
25.
van Iwaarden, J. F., J. C. Pikaar, J. Storm, E. Brouwer, J. Verhoef, R. S. Oosting, L. M. van Golde, and J. A. van Strip. 1994. Binding of surfactant
protein A to the lipid A moiety of bacterial lipopolysaccharides. Biochem.
J. 303(Pt. 2):407-411.
26.
Kuan, S. F.,
K. Rust, and
E. Crouch.
1992.
Interactions of surfactant protein
D with bacterial lipopolysaccharides: surfactant protein D is an Escherichia coli-binding protein in bronchoalveolar lavage.
J. Clin. Invest.
90:
97-106
[Medline].
27.
Wright, S. D.,
R. A. Ramos,
P. S. Tobias,
R. J. Ulevitch, and
J. C. Mathison.
1990.
CD14, a receptor for complexes of lipopolysaccharide (LPS) and
LPS binding protein [see comments].
Science
249:
1431-1433
[Medline].
28.
Stamme, C., and J. R. Wright. 1999. Surfactant protein A enhances the
binding and deacylation of E. coli LPS by alveolar macrophages. Am. J. Physiol. 276(3, Pt. 1):L540-L547.
29.
Fiebich, B. L.,
R. D. Butcher, and
P. J. Gebicke-Haeter.
1998.
Protein kianse C-mediated regulation of inducible nitric oxide synthase expression
in cultured microglial cells.
J. Neuroimmunol.
9:
170-178
30.
Ruetten, H.,
C. Thiemermann, and
M. Perretti.
1999.
Upregulation of
ICAM-1 expression on J774.2 macrophages by endotoxin involves activation of NF-kappaB but not protein tyrosine kinase: comparison to induction of iNOS.
Mediators Inflamm.
8:
77-84
.
31.
Mustafa, S. B., and M. S. Olson. 1999. Effects of calcium channel antagonists on LPS-induced hepatic iNOS expression. Am. J. Physiol. 277(2, Pt.
1):G351-G360.
32.
Koptides, M., T. M. Umstead, J. Floros, and D. S. Phelps. 1997. Surfactant
protein A activates NF-kappa B in the THP-1 monocytic cell line. Am. J. Physiol. 273(2, Pt. 1):L382-L388.
33.
Sakatsume, M., and
D. S. Finbloom.
1996.
Modulation of the expression of
the IFN-gamma receptor beta-chain controls responsiveness to IFN-gamma in human peripheral blood T cells.
J. Immunol.
156:
4160-4166
[Abstract].
34.
Schagat, T. L.,
M. J. Tino, and
J. R. Wright.
1999.
Regulation of protein
phosphorylation and pathogen phagocytosis by surfactant protein A.
Infect. Immun.
67:
4693-4699
[Abstract/Full Text].
35.
Borron, P.,
J. C. McIntosh,
T. R. Korfhagen,
J. A. Whitsett,
J. Taylor, and
J. R. Wright.
2000.
Surfactant-associated protein A inhibits LPS-induced
cytokine and nitric oxide production in vivo.
Am. J. Physiol. (Lung Cell.
Mol. Physiol.)
278:
L840-L847
This article has been cited by other articles:
![]() |
C. Moulakakis, S. Adam, U. Seitzer, A. B. Schromm, M. Leitges, and C. Stamme Surfactant Protein A Activation of Atypical Protein Kinase C {zeta} in I{kappa}B-{alpha}-Dependent Anti-Inflammatory Immune Regulation J. Immunol., October 1, 2007; 179(7): 4480 - 4491. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Pastva, J. R. Wright, and K. L. Williams Immunomodulatory Roles of Surfactant Proteins A and D: Implications in Lung Disease Proceedings of the ATS, July 1, 2007; 4(3): 252 - 257. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Fraser, M. Arora, S. S. Bohlson, E. Lozano, and A. J. Tenner Generation of Inhibitory NF{kappa}B Complexes and Phosphorylated cAMP Response Element-binding Protein Correlates with the Anti-inflammatory Activity of Complement Protein C1q in Human Monocytes J. Biol. Chem., March 9, 2007; 282(10): 7360 - 7367. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Fraser, S. S. Bohlson, N. Jasinskiene, N. Rawal, G. Palmarini, S. Ruiz, R. Rochford, and A. J. Tenner C1q and MBL, components of the innate immune system, influence monocyte cytokine expression J. Leukoc. Biol., July 1, 2006; 80(1): 107 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. Young, M. T. Borchers, H. L. Allen, R. S. Gibbons, and F. X. McCormack Lung-Restricted Macrophage Activation in the Pearl Mouse Model of Hermansky-Pudlak Syndrome J. Immunol., April 1, 2006; 176(7): 4361 - 4368. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Yang, J. Szeliga, J. Jordan, S. Faske, Z. Sever-Chroneos, B. Dorsett, R. E. Christian, R. E. Settlage, J. Shabanowitz, D. F. Hunt, et al. Identification of the Surfactant Protein A Receptor 210 as the Unconventional Myosin 18A J. Biol. Chem., October 14, 2005; 280(41): 34447 - 34457. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Matalon and J. R. Wright Surfactant Proteins and Inflammation: The Yin and the Yang Am. J. Respir. Cell Mol. Biol., December 1, 2004; 31(6): 585 - 586. [Full Text] [PDF] |
||||
![]() |
Y. Wu, S. Adam, L. Hamann, H. Heine, A. J. Ulmer, U. Buwitt-Beckmann, and C. Stamme Accumulation of Inhibitory {kappa}B-{alpha} as a Mechanism Contributing to the Anti-Inflammatory Effects of Surfactant Protein-A Am. J. Respir. Cell Mol. Biol., December 1, 2004; 31(6): 587 - 594. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Huang, G. Wang, D. S. Phelps, H. Al-Mondhiry, and J. Floros Human SP-A genetic variants and bleomycin-induced cytokine production by THP-1 cells: effect of ozone-induced SP-A oxidation Am J Physiol Lung Cell Mol Physiol, March 1, 2004; 286(3): L546 - L553. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Alcorn and J. R. Wright Surfactant protein A inhibits alveolar macrophage cytokine production by CD14-independent pathway Am J Physiol Lung Cell Mol Physiol, January 1, 2004; 286(1): L129 - L136. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hussain, J. R. Wright, and W. J. Martin II Surfactant Protein A Decreases Nitric Oxide Production by Macrophages in a Tumor Necrosis Factor-{alpha}-Dependent Mechanism Am. J. Respir. Cell Mol. Biol., April 1, 2003; 28(4): 520 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Schagat, J. A. Wofford, K. E. Greene, and J. R. Wright Surfactant protein A differentially regulates peripheral and inflammatory neutrophil chemotaxis Am J Physiol Lung Cell Mol Physiol, January 1, 2003; 284(1): L140 - L147. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Stamme, M. Muller, L. Hamann, T. Gutsmann, and U. Seydel Surfactant Protein A Inhibits Lipopolysaccharide-Induced Immune Cell Activation by Preventing the Interaction of Lipopolysaccharide with Lipopolysaccharide-Binding Protein Am. J. Respir. Cell Mol. Biol., September 1, 2002; 27(3): 353 - 360. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Guillot, V. Balloy, F. X. McCormack, D. T. Golenbock, M. Chignard, and M. Si-Tahar Cutting Edge: The Immunostimulatory Activity of the Lung Surfactant Protein-A Involves Toll-Like Receptor 4 J. Immunol., June 15, 2002; 168(12): 5989 - 5992. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.V. Pechkovsky, G. Zissel, C. Stamme, T. Goldmann, H. Ari Jaffe, M. Einhaus, C. Taube, H. Magnussen, M. Schlaak, and J. Muller-Quernheim Human alveolar epithelial cells induce nitric oxide synthase-2 expression in alveolar macrophages Eur. Respir. J., April 1, 2002; 19(4): 672 - 683. [Abstract] [Full Text] [PDF] |
||||
![]() |
|